UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 223

Sortiert nach

Bromodomain inhibitors a decade later: a promise unfulfilled?

British journal of cancer, 2020-12, Vol.123 (12), p.1713-1714

2020

Volltextzugriff (PDF)

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

Clinical cancer research, 2008-08, Vol.14 (16), p.5000-5005

2008

Volltextzugriff (PDF)

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2117-2124

2017

Volltextzugriff (PDF)

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Cell, 2018-02, Vol.172 (4), p.825-840.e18

2018

Volltextzugriff (PDF)

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-07, Vol.22 (13), p.3157-3163

2016

Volltextzugriff (PDF)

Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer

Journal of clinical oncology, 2017-11, Vol.35 (31), p.3601-3609

2017

Volltextzugriff (PDF)

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

JAMA oncology, 2019-03, Vol.5 (3), p.393

2019

Volltextzugriff (PDF)

Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?

Clinical cancer research, 2012-12, Vol.18 (24), p.6574-6579

2012

Volltextzugriff (PDF)

Treatment at high‐volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer

Cancer, 2017-10, Vol.123 (20), p.3933-3942

2017

Volltextzugriff (PDF)

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Journal of clinical oncology, 2008-01, Vol.26 (3), p.361-367

2008

Volltextzugriff (PDF)

Autophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation

Journal of cellular and molecular medicine, 2010-10, Vol.14 (10), p.2448-2459

2010

Volltextzugriff (PDF)

Vascular-disrupting agents in oncology

Expert opinion on investigational drugs, 2013-03, Vol.22 (3), p.317-328

2013

Volltextzugriff (PDF)

Heat shock proteins: a potential anticancer target

Current drug targets, 2011-12, Vol.12 (14), p.2001

2011

Volltextzugriff (PDF)

A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma

Clinical cancer research, 2020-06, Vol.26 (12), p.2819-2826

2020

Volltextzugriff (PDF)

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

Clinical cancer research, 2014-04, Vol.20 (7), p.1900-1909

2014

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Volltextzugriff (PDF)

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-06, Vol.15 (12), p.4207-4212

2009

Volltextzugriff (PDF)

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

British journal of cancer, 2017-10, Vol.117 (9), p.1258-1268

2017

Volltextzugriff (PDF)

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas

Oncotarget, 2017-10, Vol.8 (49), p.86769-86783

2017

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

Clinical cancer research, 2011-01, Vol.17 (2), p.363-371

2011

Volltextzugriff (PDF)

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms

PloS one, 2019-09, Vol.14 (9), p.e0221994-e0221994

2019

Volltextzugriff (PDF)

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

Clinical cancer research, 2010-01, Vol.16 (1), p.141-153

2010

Volltextzugriff (PDF)

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

Cancer research (Chicago, Ill.), 2021-12, Vol.81 (24), p.6273-6280

2021

Volltextzugriff (PDF)

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.145-151

2017

Volltextzugriff (PDF)

Stage I HPV‐positive oropharyngeal cancer: Should all patients receive similar treatments?

Cancer, 2020-01, Vol.126 (1), p.58-66

2020

Volltextzugriff (PDF)

1 – 25 von 223

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(202)
Mit Volltextzugriff
(204)

Publikationsform

Sprache

Englisch
(223)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Bromodomain inhibitors a decade later: a promise unfulfilled?

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?

Treatment at high‐volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Autophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation

Vascular-disrupting agents in oncology

Heat shock proteins: a potential anticancer target

A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

Stage I HPV‐positive oropharyngeal cancer: Should all patients receive similar treatments?

Suchergebnisse filtern